Chimeric Antigen Receptor (CAR) T cell Immunotherapy- Competitive Landscape, Pipeline and Market Analysis, 2018
This report can be delivered to the clients within 24 hours
'Chimeric Antigen Receptor (CAR) T cell Immunotherapy- Competitive Landscape, Pipeline and Market Analysis, 2018', report provides comprehensive Insight about marketed and pipeline drugs across this Immunotherapy. The report provides the detailed analysis of 190+ products along with 60+ companies involved. Celgene Corporation and bluebird bio has been granted Breakthrough Therapy Designation from FDA and Prime Eligibility from EMA for bb2121 Anti-BCMA CAR-T Cell Therapy for Relapsed and Refractory Multiple Myeloma.
Products covered by Phase
Pipeline analysis of 190+ therapeutic drugs include but are not limited to drug description and development activities focusing on clinical and non-clinical results, designations, collaborations & licensing deals, grants, technology and patent details. Report contains the development and sale activities for marketed drugs.
Therapeutic segmentation of products for Chimeric Antigen Receptor (CAR) T cell Immunotherapy
The report comprises of comparative pipeline therapeutics assessment by development stage, therapy type, molecule type, and administration route across this Immunotherapy.
METHODOLOGY
Data used in the report are sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts.
Information and data from the secondary sources have been obtained from various printable and non-printable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
SCOPE
'Chimeric Antigen Receptor (CAR) T cell Immunotherapy- Competitive Landscape, Pipeline and Market Analysis, 2018', report provides comprehensive Insight about marketed and pipeline drugs across this Immunotherapy. The report provides the detailed analysis of 190+ products along with 60+ companies involved. Celgene Corporation and bluebird bio has been granted Breakthrough Therapy Designation from FDA and Prime Eligibility from EMA for bb2121 Anti-BCMA CAR-T Cell Therapy for Relapsed and Refractory Multiple Myeloma.
Products covered by Phase
- Phase II, Phase I and IND
- Pre-clinical and Discovery
Pipeline analysis of 190+ therapeutic drugs include but are not limited to drug description and development activities focusing on clinical and non-clinical results, designations, collaborations & licensing deals, grants, technology and patent details. Report contains the development and sale activities for marketed drugs.
Therapeutic segmentation of products for Chimeric Antigen Receptor (CAR) T cell Immunotherapy
The report comprises of comparative pipeline therapeutics assessment by development stage, therapy type, molecule type, and administration route across this Immunotherapy.
METHODOLOGY
Data used in the report are sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts.
Information and data from the secondary sources have been obtained from various printable and non-printable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
SCOPE
- The report provides competitive pipeline landscape of Chimeric Antigen Receptor (CAR) T cell Immunotherapy
- The report provides the marketed drugs information including its sales, development activities and details of patent expiry
- The report provides the insight of current and future market for Chimeric Antigen Receptor (CAR) T cell Immunotherapy
- The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
- Coverage of the Chimeric Antigen Receptor (CAR) T cell Immunotherapy pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
- The report reviews key players involved in the therapeutics development for Chimeric Antigen Receptor (CAR) T cell Immunotherapy and also provide company profiling
- Pipeline products coverage based on various stages of development ranging from mid stage till discovery stages
- Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type
- Identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage
- Establish a comprehensive understanding of the current pipeline scenario across Chimeric Antigen Receptor (CAR) T cell Immunotherapy to formulate effective R&D strategies
- Assess challenges and opportunities that influence Chimeric Antigen Receptor (CAR) T cell Immunotherapy R&D
- Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
- Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine
- Devise corrective measures for pipeline projects by understanding Chimeric Antigen Receptor (CAR) T cell Immunotherapy pipeline depth and focus of Indication therapeutics
- Developing strategic initiatives to support your drug development activities
- Devise in licensing and out licensing strategies by identifying prospective partners with progressing projects for Chimeric Antigen Receptor (CAR) T cell Immunotherapy to enhance and expand business potential and scope
- Provides strategically significant competitor information, analysis, and Insight to formulate effective R&D development strategies
- Our extensive domain knowledge on therapy areas support the client in decision-making process regarding their therapeutic portfolio by identifying the reason behind the inactive drugs
- Gaining a full picture of the Competitive Landscape for Evidence based Decisions
Overview
Chimeric antigen receptor (CAR) T-cells
History
CARs and Generations
Advantages of CAR-T cells
Adverse Events with CAR T-cell Therapy
Limitations of Existing Technologies for CAR T-Cells
Marketed Products
Kymriah: Novartis
Product Description
Regulatory Milestones
Research and Development
Other Clinical Activities
Product Development Activities
Pipeline Therapeutics
Clinical Phase Products
Non-Clinical Phase Products
Competitive Landscape
Comparative Analysis
Mid Stage Products (Phase II)
Comparative Analysis
AU105: Aurora BioPharma
Product Description
Research and Development
Product Development Activities
(The list continues)
Early Stage Products (Phase I)
Comparative Analysis
IND Stage Products
Comparative Analysis
Unknown Stage Products
Comparative Analysis
Pre-clinical and Discovery Products
Comparative Analysis
Therapeutic Assessment: Clinical Phase Products
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Appendix
Chimeric antigen receptor (CAR) T-cells
History
CARs and Generations
Advantages of CAR-T cells
Adverse Events with CAR T-cell Therapy
Limitations of Existing Technologies for CAR T-Cells
Marketed Products
Kymriah: Novartis
Product Description
Regulatory Milestones
Research and Development
Other Clinical Activities
Product Development Activities
Pipeline Therapeutics
Clinical Phase Products
Non-Clinical Phase Products
Competitive Landscape
Comparative Analysis
Mid Stage Products (Phase II)
Comparative Analysis
AU105: Aurora BioPharma
Product Description
Research and Development
Product Development Activities
(The list continues)
Early Stage Products (Phase I)
Comparative Analysis
IND Stage Products
Comparative Analysis
Unknown Stage Products
Comparative Analysis
Pre-clinical and Discovery Products
Comparative Analysis
Therapeutic Assessment: Clinical Phase Products
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Appendix
LIST OF TABLES
Table 1: CARs Generations
Table 2: CARs Generations-Associated Target Antigens and Indications
Table 3: Total Products for CART Cell therapy
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I)
Table 6: IND Stage Products
Table 7: Unknown Stage Products
Table 8: Pre-clinical Stage Products
Table 9: Discovery Stage Products
Table 10: Assessment by Route of Administration
Table 11:: Assessment by Stage and Route of Administration
Table 1: CARs Generations
Table 2: CARs Generations-Associated Target Antigens and Indications
Table 3: Total Products for CART Cell therapy
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I)
Table 6: IND Stage Products
Table 7: Unknown Stage Products
Table 8: Pre-clinical Stage Products
Table 9: Discovery Stage Products
Table 10: Assessment by Route of Administration
Table 11:: Assessment by Stage and Route of Administration
LIST OF FIGURES
Figure 1: Total Products for CART Cell therapy
Figure 2: Mid Stage Products (Phase II)
Figure 3: Early Stage Products (Phase I)
Figure 4: IND Stage Products
Figure 5: Unknown Stage Products
Figure 6: Pre-clinical and Discovery Stage Products
Figure 7: Assessment by Route of Administration
Figure 8: Assessment by Stage and Route of Administration
Figure 1: Total Products for CART Cell therapy
Figure 2: Mid Stage Products (Phase II)
Figure 3: Early Stage Products (Phase I)
Figure 4: IND Stage Products
Figure 5: Unknown Stage Products
Figure 6: Pre-clinical and Discovery Stage Products
Figure 7: Assessment by Route of Administration
Figure 8: Assessment by Stage and Route of Administration
